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Abstract 
Negative symptoms in schizophrenia have been suggested to map onto two distinct factors – amotivation 
and diminished expression. Only recently, two-factor solutions for measuring negative symptoms have 
been proposed for the Positive and Negative Symptom Scale (PANSS), the most commonly used scale to 
assess the psychopathology of patients with schizophrenia. We aimed to validate the PANSS two-factor 
structure on a clinical, behavioural and neural level.  
For this multi-level validation, we reanalysed several datasets with patients for whom both the Brief 
Negative Symptom Assessment Scale (BNSS) and PANSS data were collected. We used a clinical dataset 
(n=120) as well as behavioural data from an effort-based decision making task (n=31) and functional 
neuroimaging data from a monetary incentive delay task (n=41). Both tasks have previously been shown 
to be associated with BNSS amotivation.  
On the clinical level, the PANSS amotivation and diminished expression were highly correlated with their 
BNSS counterparts. On the behavioural level, we found that the PANSS amotivation factor but not the 
diminished expression factor specifically associated with willingness to invest effort to obtain a reward. 
On the neural level, PANSS amotivation was specifically related to reduced ventral striatal activation during 
reward anticipation. 
Our data confirm that the PANSS clearly allows distinguishing amotivation from diminished expression, as 
it relates selectively to specific aspects of behaviour and brain function. Our results will allow a re-analysis 
and sharing of existing datasets that used the PANSS to further substantiate the distinction between the 





According to a recent consensus, negative symptoms in schizophrenia are composed of five domains, 
namely, asociality, anhedonia, avolition, blunted affect, and alogia (Kirkpatrick et al., 2006).  The bulk of 
previous research has studied the relationship between patients’ behaviour, cognitive ability, brain 
function and response to treatment in relation to negative symptoms as a unitary construct. However, it 
has been suggested that at least two distinct factors constitute negative symptoms and the current DSM-
V distinguishes between two subdomains: amotivation (including avolition, asociality and anhedonia) and 
diminished expression (including blunted affect and alogia) (Blanchard and Cohen, 2005, Kirkpatrick, 
2014). This distinction appears important because the two factors relate to different aspects of behaviour 
and might require different medical and psychological treatment (Dowd et al., 2016, Gold et al., 2012) .  
It is important to note that Strauss and colleagues provided strong statistical evidence for a five-factor 
model of negative symptoms corresponding to the five domains mentioned above (Ahmed et al., 2018, 
Strauss et al., 2018, San Ang et al., 2019). However, it remains to be determined which level of granularity 
is the most promising for understanding the pathophysiology of negative symptoms and developing new 
treatment approaches. At present, the two-factor approach has been successfully used in studies of 
behaviour and brain function, while less data are available for the five-factor approach (Kirschner et al., 
2016, Hartmann et al., 2014, Moran et al., 2019, Waltz et al., 2018).   
The most widely used scale for symptom assessment in research and clinical trials in schizophrenia is the 
Positive and Negative Symptom Scale (PANSS) (Kay et al., 1987). This scale allows a broad assessment of 
positive, negative and general symptoms. It has been argued, however, that the negative symptom 
subscale is ill-suited for specifically studying negative symptoms, as it disregards some items pertaining to 
negative symptoms (e.g. appetitive & consummatory aspects of anhedonia) and includes items that relate 
to other symptom domains (e.g. stereotyped thinking, difficulty in abstract thinking) (Garcia-Portilla et al., 
2015, Kirkpatrick et al., 2006).  Importantly, two-factor solutions for negative symptoms have been 
described for the PANSS – (social) amotivation and diminished expression (Table 2) (Fervaha et al., 2014, 
Liemburg et al., 2013). These solutions include items from both the negative and the general subscales.  It 
is unclear, however, how the two factors identified in the PANSS relate to the two factors of negative 
symptoms measured by specific negative symptom scales and whether they relate in a similar fashion to 
behaviour and brain function. 
In order to assess the five domains of negative symptoms defined in the NIMH-Matrics consensus 
statement two newer specific scales were developed: the Brief Negative Symptom Assessment Scale 
(BNSS) (Strauss et al., 2012a, Strauss et al., 2012b) and the Comprehensive Assessment Interview for 
Negative Symptoms (CAINS) (Kring et al., 2013). While assessing the five identified domains of negative 
symptoms, both scales allow to define a two-factor structure, which has been found in several factor 
analytic studies (Mucci et al., 2015, Strauss et al., 2012a, Horan et al., 2011). 
Importantly, recent work shows that amotivation and diminished expression as evaluated by the BNSS 
(but also by the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1982) relate 
differentially to several aspects of behaviour and have different underlying neural substrates. For example, 
amotivation, but not diminished expression, has been associated with deficits in reward learning and 
effort-based decision-making (Hartmann et al., 2014, Hartmann et al., 2015, Gold et al., 2012, Waltz et al., 
2007, Raffard et al., 2016, Grant and Beck, 2008). On the other hand, diminished expression, but not 
amotivation, has been associated with abnormalities in emotion perception and in the execution and 
imitation of facial expressions (Gur et al., 2006, Lepage et al., 2011). However, these findings result from 
a limited number of studies with mostly small sample sizes and have therefore still to be considered with 
caution.  
In the present manuscript, we aimed for the first time to validate the PANSS two-factor structure not only 
on the clinical but also on a behavioural and neural level. Such a novel multilevel validation would grant 
neuroscientific validity to the concept of amotivation, linking clinical observations of negative symptoms 
to pathophysiology. This confirmation of the PANSS two-factor structure in turn would allow a fine-grained 
re-analysis of the existing data on pathophysiology as well as treatment of negative symptoms and would 
facilitate including factor scores in planned trials. 
Specifically, we relied on several datasets with patients for whom both BNSS and PANSS data were 
collected and we tested the following hypotheses (see Methods section for detailed information on the 
patient cohorts). First, if indeed the factors amotivation and diminished expression as measured by the 
two scales represent the same phenomena, we should observe stronger correlations between the same 
factors (e.g. BNSS amotivation & PANSS amotivation) than between the different factors (e.g. BNSS 
amotivation & PANSS diminished expression). Second, using the PANSS amotivation measure we should 
replicate the previously reported (Hartmann et al., 2015) correlation between amotivation (as measured 
by BNSS) and the discounting of reward when physical effort is required. Moreover, this relation should 
be specific for amotivation rather than diminished expression. Third, following on from our neural 
findings (Kirschner et al., 2016, Stepien et al., 2018), we expected to observe a negative correlation of 
ventral striatum activity during reward anticipation with the amotivation, but not the diminished 
expression factor when using the PANSS instead of the BNSS. 
 
Methods 
Psychopathological assessment and factor models used in all studies 
 In all patients, the diagnosis of schizophrenia or schizoaffective disorder was confirmed using the Mini-
International Neuropsychiatric Interview for DSM-IV (MINI). Exclusion criteria comprised: presence of 
other DSM-IV Axis I disorders (in particular, current substance use disorder and major depressive disorder); 
presence of florid psychotic symptomatology (i.e., a score exceeding 4 on the positive subscale of the 
PANSS); presence of extrapyramidal side-effects (total score exceeding 2 on the Modified Sympson-Angus 
Scale) and medication with more than 1 mg lorazepam per day. These exclusion criteria aimed at limiting 
the impact of secondary negative symptoms on the present results (Kirschner et al., 2017). 
 
Negative symptoms were assessed with the BNSS, the PANSS and the SANS. The BNSS served as the 
primary clinical outcome for the present studies. The validated German version of the scale was employed. 
All raters were trained by the senior author (SK) who was responsible for the German translation. 
 
In order to distinguish between the factors amotivation and diminished expression we used the existing 
factor solutions from the literature for the three scales (Table 2).  For the BNSS, we adopted the two-factor 
solution proposed by Mucci and colleagues (2015), which excludes the item “lack of normal distress”. For 
the PANSS we used the factor structure proposed by Fervaha and colleagues (2014) that does not include 
two additional items included in the solution of Liemburg and colleagues (2013) (see discussion for more 
detail). However, the results of all analyses conducted were similar for the two solutions.  
  
In the main manuscript, we focus on the PANSS and the BNSS. However, to provide a complete overview 
we also performed all analyses with a two-factor solution for the SANS (Strauss et al., 2013). The results 




Study 1 – Clinical validation 
The goal of the first study was to validate the amotivation – diminished expression distinction in the PANSS 
don a clinical level. 
Participants 
Patients’ demographics are presented in Table 1. Data from 120 patients from different studies were used 
to increase power. 75 patients are from the study by Bischof et al., 2016 (Bischof et al., 2016), data from 
31 of these patients were used in Study 2 of this manuscript, and data of 27 patients in Study 3.   
Data from the remaining 45 patients were collected as part of a yet unpublished study in our laboratory. 
Thus, 75 data points were only used in Study 1 and do not overlap with the other two studies presented 
in this manuscript. 
110 patients fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 
criteria for schizophrenia and 10 – for schizoaffective disorder (not in a mood episode at the time of 




Jamovi was used to perform the correlations (The jamovi project (2019), jamovi (Version 0.9). We 
conducted Pearson correlational analyses between BNSS and PANSS factors using the ratings of all 120 
participants. In addition, we performed the same analysis correlating PANSS and SANS factors using data 
from the 75 participants for whom SANS scores were available (see supplementary material). We used the 
cocor R package to compare the strengths of the correlations (Diedenhofen and Musch, 2015). The 
significance level was set to p=0.05. 
 
Study 2 – Behavioural validation 
The second study aimed to validate the PANSS factor structure on a behavioural level. For this purpose, 
we employed data from Hartmann and colleagues (2015), which showed a negative correlation between 
willingness to exert effort and the factor amotivation of the BNSS. We used the same analytic approach, 
but used the PANSS factors instead of the BNSS factors.  
Participants 
Data from the original 31 patients were used for the analysis (Table 1). Patients met the DSM-IV diagnostic 
criteria for schizophrenia (n=25) or schizoaffective disorder (n=6) (confirmed by the MINI). All patients 
were clinically and pharmacologically stable at the time of the study. The same exclusion criteria as for 
Study 1 were applied. 27 patients were part of the Study 1 cohort, namely, their data represents a subset 
of the 75 patients from the work of Bischof et al., 2016, and 4 patients did not overlap with the other 
studies of this manuscript. 
 
Effort task 
The task consisted of a series of choices between two options: receiving a small default amount of money 
(1 CHF) while exerting no effort versus receiving a larger amount (e.g. 3 CHF) contingent on the exertion 
of a certain level of physical effort. Physical effort involved squeezing a hand-held dynamometer with the 
dominant hand during a 3.5s interval (in the no-effort choice participants had to wait for 3.5s before 
receiving the reward). The effortful choice comprised one of four effort levels: 40%, 60%, 80% and 100% 
of maximal strength. Maximal strength was determined at the beginning of the experiment in a calibration 
trial, where participants had to press the handgrip as hard as they could. The following amounts 
constituted the reward on effortful trials: 1.5, 2, 2.5, 3, 5 CHF (1 CHF ≈ 1 $). Participants performed 80 
trials (each effort level was repeated 4 times).  
This task allows estimating the reward at which participants are indifferent between a no-effort choice 
and a particular effortful option (i.e. indifference points) by fitting a logistic function through the fraction 
of all effortful choices for a given reward level. The indifference points further allow calculating the relative 
subjective value (SV) of reward for each participant, that is, how the four effort levels reduce the value of 
a given reward. SV is calculated by dividing the default reward of 1 CHF by the respective indifference 
reward amounts. Finally, connecting SVs over the four effort levels we used the area under the curve (AUC) 
as a single measure of willingness to exert effort. Smaller AUC corresponds to steeper effort discounting.   
 
Statistical Analyses 
The present analysis aimed to replicate the original behavioural results obtained with the BNSS. The 
authors correlated the AUC with the amotivation and diminished expression factors of the BNSS. We thus 
performed the correlational analysis on the original data of this study (AUC) but used the two factors from 
the PANSS and SANS scores, collected at the time of the study. 
 
Study 3 – Neural validation 
The third analysis aimed to validate the PANSS factor structure on the neural level. For this purpose, we 
employed data from the studies by Kirschner and colleagues (2016), and by Stepien and colleagues (2018), 
which showed a negative correlation between ventral striatal activation during reward anticipation and 
the factor amotivation of the BNSS. We used the same analytic approach, but used the PANSS factors 
instead of the BNSS factors. Since the main objective of the present analysis concerns the neural validation 
of the PANSS factors, we focussed on ventral striatal activation as the best established neural correlate of 
amotivation and did not perform a whole-brain analysis.  
Participants 
27 clinically stable patients fulfilling the diagnostic criteria of DSM-IV for schizophrenia participated in the 
study by Kirschner and colleagues (2016). These patients were also part of the 75 patients (Bischof et al., 
2016) from Study 1 and partially overlapped with patients in Study 2 (9 patients were the same). Additional 
data from 16 patients with schizophrenia were included. These patients originally participated in the study 
by Stepien and colleagues (2018). These patients did not overlap with any patients from Study 1 or 2. Two 
patients from the Kirschner et al. study also participated in the Stepien et al. study. We excluded their data 
for the study by Kirschner and colleagues (2016). Thus, data from 41 participants was analysed. 
 
Task design  
In both studies, participants performed a version of the Monetary Incentive Delay Task (MID) originally 
developed by Simon and colleagues (Simon et al., 2015). At the beginning of each trial, a cue informed the 
participants of the maximal amount they could win in that trial (0 CHF, 0.40 CHF or 2 CHF). Next, 
participants had to identify an outlier from three circular stimuli as fast and as correctly as possible. 
Feedback on how much they won was presented on every trial and depended on the speed of the 
participants’ response. There was a total of 72 trials in the experiment. 
Functional Magnetic Resonance Imaging 
Imaging was performed at the MR Zentrum of the Psychiatric Hospital, University of Zurich, using a Philips 
Achieva 3.0 T magnetic resonance scanner with a 32-channel SENSE head coil. The task was conducted in 
two runs, 195 images in each run. A gradient-echo T2*-weighted echo-planar image (EPI) sequence was 
used with 38 slices acquired in ascending order. Acquired in-plane resolution was 3 × 3 mm2, 3 mm slice 
thickness and 0.5 mm gap width over a field of view of 240 × 240 mm, repetition time 2000 ms, echo time 
25 ms and a flip angle of 82°. The first 5 scans were discarded to eliminate the influence of T1 saturation 
effects. Slices were aligned with the anterior–posterior commissure. Anatomical data were acquired using 
an ultrafast gradient echo T1-weighted sequence in 160 sagittal plane slices of 240 × 240 mm resulting in 
1 × 1 × 1 mm voxels. 
 
Analyses 
fMRI analyses were performed with SPM8. During preprocessing functional images were corrected for 
differences in the time of slice acquisition and motion using the realign and unwarp functions of SPM8. 
Correction for combined static and dynamic distortions was done using a voxel displacement map, 
calculated from double phase and magnitude field map data. Segmentation, bias correction and spatial 
normalization was performed. Images were smoothed using a 6 mm full-width at half-maximum Gaussian 
kernel. Participants with translational head movement greater than 3 mm or extensive signal dropout in 
the EPI sequences were excluded to ensure adequate data quality.  
 
For the first level analysis, a general linear model (GLM) approach was used in an event-related design. 
Three separate regressors were used for the anticipation phases of the three reward levels: anticipation 
of no reward (0 CHF), low reward (0.40 CHF) and high reward (2 CHF). Similarly, 3 regressors were included 
for the outcome phase. For the low and high reward conditions the outcome regressors were 
parametrically modulated by the amount the participants won on each trial. Target presentation and error 
anticipation, target and outcome phase were modelled as regressors of no interest. All explanatory 
variables were convolved using the canonical hemodynamic response function. The contrast “high reward 
(2 CHF) anticipation versus no reward (0 CHF) anticipation” was calculated for reward anticipation. 
 
The anticipation regressor of interest included the cue and the delay phases of each trial. Thus, as 
mentioned above, there were three regressors of interest (anticipation of 0 CHF, 0.40 CHF or 2 CHF). Based 
on a meta-analysis (Knutson and Greer, 2008), the ventral striatum was defined as the region of interest 
during reward anticipation (left: x, y, z = −12, 10, −2; right: x, y, z = 10, 8, 0). Mean percent signal change 
was extracted with the REX toolbox (http://web.mit.edu/swg/software.htm). The data from the two 
studies were pooled and correlations between the percent signal change in the ventral striatum and the 




Study 1 – Clinical Validation 
Comparing the two PANSS factors to the two BNSS factors 
As predicted by the first hypothesis, we found that the PANSS amotivation factor was highly correlated 
with the BNSS amotivation factor (Figure 1A). Importantly, this correlation was significantly stronger than 
the correlation between the PANSS amotivation factor and the BNSS diminished expression score (z=5.2, 
p<0.0001). Furthermore, the PANSS diminished expression factor was highly correlated with the BNSS 
diminished expression factor (Figure 1D) and this correlation was significantly stronger than the 
correlation between the PANSS diminished expression factor and the BNSS amotivation factor (z=5.4, 
p<0.0001).  Thus, the two-factor solutions of the two scales converged, suggesting that they measure 
amotivation and diminished expression similarly. 
In an additional analysis, we included only the 75 patients which exclusively participated in Study 1 and 
not in Study 2 or 3 in order assure full independence. The results for this subgroup were almost identical 
to the full sample (see supplementary material, and supplementary table S5).   
Comparing the PANSS amotivation factor to the three sub-domains of BNSS amotivation 
While our main hypotheses concerned the correspondence between the PANSS and BNSS two-factor 
model, we were also interested in the association of the PANSS two-factor model with the BNSS five-factor 
model (see Table 4 & 5). PANSS amotivation was highly and significantly correlated with each of the three 
sub-domains composing BNSS amotivation, namely, anhedonia, asociality and avolition (the correlation 
between PANSS amotivation and BNSS asociality was significantly stronger than that between PANSS 
amotivation and BNSS anhedonia (z = -2.0, p=0.045)). Similarly, PANSS diminished expression correlated 
significantly with BNSS blunted affect and alogia.  
 
Study 2 - Behavioural validation 
Correlation between effort discounting and amotivation  
We next performed correlations between the willingness to exert effort (AUC) from the study by Hartmann 
and colleagues (2015) and the amotivation factors extracted from the different negative symptoms scales 
(Table 6, Figure 2). The original study (Hartmann et al., 2015) found a significant negative correlation 
between AUC and the factor amotivation of the BNSS (r=-0.67, p<0.0001) but no significant correlation 
with the diminished expression factor (r=-0.14, p=0.45). Thus, patients who had more amotivation 
symptoms discounted physical effort more strongly. In other words, patients with higher amotivation 
scores were less willing to work for reward in the behavioural task. 
In the present analysis we found a highly significant negative correlation between the willingness to exert 
effort and the PANSS amotivation factor (PANSS: r=-0.49, p=0.005). There was no significant correlation 
with the PANSS diminished expression factor (PANSS: r=-0.08, p=0.68). The two correlations were 
significantly different from each other (z=-3.0, p=0.003). Thus, the pattern of results is similar to the one 
obtained for the BNSS factors. However, the size of the correlation with PANSS amotivation was 
significantly smaller than with BNSS amotivation (z=-2.1, p=0.036). Thus, at the behavioural level the two 
scales appear to relate similarly to an independent measure of motivation, in line with the second 
hypothesis. 
 
Study 3 – Neural validation 
Correlation between ventral striatal signal change and amotivation 
Our previous work has shown that activity in the ventral striatum during reward anticipation is negatively 
correlated with the amotivation but not the diminished expression factor of the BNSS (Kirschner et al., 
2016, Stepien et al., 2018). We pooled the patients in these two studies in order to test the relation of 
PANSS and SANS to the signal change in the left ventral striatum (hypothesis 3).  
In the pooled dataset, as expected, left ventral striatal activation showed a highly significant negative 
association with BNSS amotivation (r=-0.53, p<0.001), but not with BNSS diminished expression (r=0.05, 
p=0.78). Corroborating hypothesis 3, left ventral striatal activation was negatively associated with PANSS 
amotivation (r=-0.33, p=0.04) but not with PANSS diminished expression (r=0.009, p=0.96) and the 
difference between these correlations was significant (z=-2.5, p=0.013). Thus, similar to BNSS the PANSS 
factors have distinct relationships to left ventral striatum signal change during reward anticipation. 
However, left ventral striatum signal correlated numerically and trend-level statistically (z=-1.9, p=0.053) 




The goal of the present paper was to evaluate whether the scale most commonly used in the study of 
schizophrenia – the PANSS – allows maintaining the two-factor distinction between amotivation and 
diminished expression similarly to the more recent and more complete BNSS. We conducted three 
correlational analyses on data at three processing levels – symptomatic, behavioural and neural, which 
showed that this was indeed the case, although the association between PANSS amotivation and its 
behavioural and neural correlates was weaker than for BNSS amotivation.  
First, on the clinical level, the correlations between BNSS and PANSS factors were significantly stronger 
within the same factor (within amotivation for BNSS and PANSS and within diminished expression for BNSS 
and PANSS) than across the two factors (e.g. BNSS amotivation and PANSS diminished expression).  Thus, 
despite the differences between the scales, by following the factor-analytic structure defined in previous 
research, we show that BNSS and PANSS factors reflect similar symptom clusters.  
Next, we show that the PANSS amotivation factor, but not the diminished expression factor, is specifically 
associated with reward discounting for physical effort. The observed effect size is smaller when using 
PANSS amotivation than the amotivation factor from the BNSS – a more specific negative symptom scale. 
The same differential result is obtained using the SANS amotivation / diminished expression factors. 
Further, in an enlarged sample we confirm that reduced left ventral striatal signal change during reward 
anticipation is selectively associated with PANSS amotivation, but not with diminished expression 
(Kirschner et al., 2016, Stepien et al., 2018). A similar result is observed when using the SANS. In line with 
the results for the effort discounting task, the observed effect size for the association with ventral striatal 
signal change is somewhat smaller when using PANSS amotivation than with the two specific negative 
symptom scales BNSS and SANS.   
The behavioural and neuroimaging results clearly show that the PANSS allows disentangling specific 
correlates for amotivation in comparison to diminished expression. Thus, they confirm the specific 
association shown on the clinical level and support the use of the PANSS for measuring the two symptom 
dimensions of amotivation and diminished expression. These results are in line with recent work showing 
an association of the PANSS amotivation factor with reduced ventral striatum activity and reduced effortful 
behaviour (Caravaggio et al., 2018, Chang et al., 2019). The fact that the observed effect size for the 
associations with PANSS amotivation is somewhat smaller than with the BNSS can be explained by the 
restriction of the PANSS to social amotivation, which does not cover the full range of amotivation 
symptoms. This is evidenced by the stronger correlation between PANSS amotivation and BNSS asociality 
(which corresponds to social amotivation) than between PANSS amotivation and BNSS anhedonia, the 
latter not being measured by the PANSS. The BNSS, on the other hand, explores motivation for social, 
work/study/therapy and leisure activities. Despite the reduced range of motivation explored by the PANSS 
it shows associations with behaviour and brain function that are comparable to the BNSS. 
Several factor solutions exist for the PANSS. The two-factor solutions for the assessment of negative 
symptoms differ in that Liemburg and colleagues (2013) include items G5 (mannerisms and posturing) and 
G13 (avolition) as part of the diminished expression factor, whereas Fervaha and colleagues (2014) do not. 
We have used this latter solution, as it is more balanced in terms of number of elements per factor and 
because G5 and G13 are not regarded as negative symptoms per se according to the NIMH-Matrics 
consensus statement. Indeed, G13, even though bearing the name “avolition”, clinically refers more to 
ambivalence and thus does not correspond to any item of the BNSS. In any case, using the PANSS factor 
solution by Liemburg and colleagues did not change the results of the present study in any meaningful 
way. 
Our results indicate that large-scale studies not primarily focusing on negative symptoms can yield 
valuable insights on amotivation and diminished expression while only employing the PANSS, as opposed 
to a specialised negative symptom scale like the BNSS or the CAINS. However, as mentioned earlier, the 
PANSS remains constrained in the way different aspects of negative symptoms are addressed. PANSS 
mainly evaluates behavioural aspects of patients’ symptoms and neglects internal experience. Similarly, 
PANSS does not measure anhedonia and the definition of avolition does not correspond to its current 
conceptualization (Kirkpatrick et al., 2006). It is thus crucial that specialised scales like the BNSS be used in 
studies directly addressing negative symptoms in order to obtain fine-grained specific results. Importantly, 
recent work has suggested that the five domains of negative symptoms represent distinct constructs and 
should be studied separately (Strauss et al., 2018, Ahmed et al., 2018). The PANSS does not allow this 
supplementary level of granularity, only afforded by specialised scales. The present data highlight the 
value of the PANSS in the study of negative symptoms. However, the BNSS, and similar scales, remain the 
clinical instruments of choice for a detailed study of this domain of psychopathology.    
The tasks used in the present studies did not aim to show specific behavioural and neural correlates for 
the diminished expression factor. So far, a comprehensive model of diminished expression has not been 
established in the literature and empirical data are generally more limited (Kaiser et al., 2017). To date, 
several studies indicate that the amotivation factor is primarily related to functional outcomes (Chang et 
al., 2016, Fervaha et al., 2015), and therefore could be thought of as more relevant and a central target 
for the development of  treatment interventions. However, previous work (Galderisi et al., 2013, Evensen 
et al., 2012), and most importantly, recent studies in large cohorts have found diminished expression to 
be linked to at least some aspects of community functioning (Liemburg et al., 2020). Furthermore, two 
recent studies needing confirmation have suggested diminished expression to respond in a similar fashion 
to pharmacological treatment interventions (Fleischhacker et al., 2019, Harvey et al., 2020) as amotivation. 
Our findings suggest that a re-analysis of existing behavioural and neuroimaging studies using the PANSS 
factor model could provide additional empirical data for these observations, allowing to develop a model 
of diminished expression. 
The present studies have several limitations. First, all ratings (PANSS, BNSS, SANS) were based on the same 
semi-structured interview for negative symptoms, which was modified from the BNSS manual. Thus, we 
cannot be certain that in a study that only uses the PANSS the distinction between factors would be as 
clear as in the present study. However, our results are coherent with previous factor analytic studies 
(Liemburg et al., 2013; Fervaha et al., 2014). Second, all ratings for one patient were made by the same 
rater, which is likely to increase correspondence between the different scales.   
Overall, our results demonstrate how behavioural and neuroimaging data can provide an additional 
validation of clinical measures. To our knowledge, our study is the first to apply this novel approach to 
negative symptoms. We consider the mutual informing of clinical and neuroscientific approaches as 
important, as future clinical scales may not only be reliable and valid at a clinical level, but also link to the 
underlying pathophysiology. This multilevel approach is in line with the RDoC framework, the goal of which 
is to establish a neuroscience-driven classification of psychiatric disorders as opposed to one that is only 
based on clinical observations (Insel, 2014, Insel et al., 2010, Cuthbert and Insel, 2013). 
Our results provide a building block for evaluating the extensive previous behavioural and brain imaging 
research using the PANSS in terms of selective relations to amotivation or diminished expression domains 
of negative symptoms. This approach is particularly valuable, as it would allow constituting data sets with 
large sample sizes increasing the power to detect the mechanisms underlying negative symptoms. These 
methodological results also promote the development of open science, making it possible to share data in 
order to construct such large samples. Thus, reliably linking the different domains of negative symptoms 
with specific pathophysiological mechanisms, such as impairments in reward processing, may create 
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Demographic, psychopathological and clinical characteristics of patients 
 
Study 1 (N=120) Study 2 (N=31) Study 3 (N=43) 
Age, years 32.4 (10.7) 30.4 (8.7) 32.2 (8) 
Sex 87 males 25 males 32 males 
Education, years 11.8 (3.3) 9.8 (1.7) 12.1 (2.6) 
Duration of illness, months 119.9 (186.6) 115.5 (97.5) 115.3 (81.5) 
Chlorpromazine equivalent, 
mg/d 
585.1 (562) 568.2 (409.97) 514.2 (457.26) 
Calgary Depression Scale for 
Schizophrenia 
2.24 (2.9) 2.42 (2.41) 2.15 (2.15) 
BNSS score 
   
Amotivation 17.03 (8.9) 16.6 (7.5) 15.09 (7.8) 
Diminished Expression 10.3 (8.3) 10.4 (6.97) 9.07 (7.6) 
PANSS score  
   
Amotivation 7.8 (3.4) 7.06 (2.7) 7.3 (3.3) 
Diminished Expression 9 (4.4) 9.06 (3.7) 8.95 (4.3) 
SANS score 
   
Amotivation 4.4 (2.2) 4.03 (1.8) 4.5 (2.2) 




Factor solutions from the literature (Mucci et al., 2015, Fervaha et al., 2014) used to calculate 
Amotivation and Diminished expression factors for BNSS and PANSS. For completeness, we also show 
the factor solution proposed by Liemburg and colleagues (2013) 
Amotivation Diminished expression 
BNSS (Mucci et al., 2015) 
Intensity of pleasure Facial expression 
Frequency of pleasure Vocal expression 
Intensity of future pleasure Expressive gestures 
Asociality: behaviour Quantity of speech 
Asociality: internal experience Spontaneous elaboration 
Avolition: behaviour  
Avolition: internal experience  
PANSS (Fervaha et al., 2014) 
Emotional withdrawal (N2) Blunted affect (N1) 
Apathetic social withdrawal (N4) Poor rapport (N3) 
Active social avoidance (G16) Lack of flow (N6) 
 Motor retardation (G7) 
PANSS (Liemburg et al. 2013)  
Emotional withdrawal (N2) Blunted affect (N1) 
Apathetic social withdrawal (N4) Poor rapport (N3) 
Active social avoidance (G16) Lack of flow (N6) 
 Motor retardation (G7) 
  Mannerisms and posturing (G5) 









Correlation matrix for BNSS and PANSS (N=120) 













 —  0.651  0.830  0.633  
   p-value  —  < .001  < .001  < .001  
BNSS Expression  
Pearson's 
r 
    —  0.665  0.909  





       —  0.684  





          —  
   p-value           —  
Table 4 
Correlation Matrix between PANSS Amotivation and BNSS Anhedonia, Avolition and Asociality (N=120) 
    
PANSS 
Amotivation 
    
PANSS Amotivation  Pearson's r  —              
   p-value  —              
BNSS Anhedonia  Pearson's r  0.696           
   p-value  < .001           
BNSS Asociality  Pearson's r  0.791        
   p-value  < .001        
BNSS Avolition  Pearson's r  0.765     
   p-value  < .001     




Correlation matrix between PANSS Diminished Expression and BNSS Blunted affect and Alogia (N=120) 
    
PANSS 
Expression 
   
PANSS Expression  Pearson's r  —           
   p-value  —           
BNSS Blunted affect  Pearson's r  0.867        
   p-value  < .001        
BNSS Alogia  Pearson's r  0.885     
   p-value  < .001     
 
Table 6 
Correlation Matrix for BNSS, PANSS and area under the curve (AUC) reflecting willingness to exert effort 
(N=31, Hartmann et al., 2015) 
    AUC 
PANSS Amotivation  Pearson's r  -0.492   
   p-value  0.005   
PANSS Expression  Pearson's r  -0.077   
   p-value  0.682   
BNSS Amotivation  Pearson's r  -0.665   
   p-value  < .001   
BNSS Expression  Pearson's r  -0.143   




Correlation Matrix between BNSS, PANSS and the left ventral striatum activation reflecting reward 
anticipation (N=41, Kirschner et al., 2016, Stepien et al., 2018) 
    left VS  
BNSS Amotivation  Pearson's r  -0.523     
   p-value  < .001     
BNSS Expression  Pearson's r  0.042     
   p-value  0.794     
PANSS Amotivation  Pearson's r  -0.326     
   p-value  0.037     
PANSS Expression  Pearson's r  0.007     








Figure 1. Pearson correlation for the factors Amotivation and Diminished expression of the BNSS and the 





Figure 2. Pearson correlations of the PANSS factors Amotivation (A) and Diminished expression (B) with 




Figure 3. Pearson correlation of the factors Amotivation (A) and Diminished expression (B) with percent 





Clinical validation of the SANS 
All the analyses described in the main text of the article were repeated using the two factors of the SANS 
(Table S1). 
Study 1 – Clinical Validation 
Comparing PANSS factors to SANS factors 
We compared the PANSS factors to the SANS factors for further validation. SANS data were available from 
75 participants of the original sample (Bischof et al., 2016); analyses were thus performed on data from 
these participants for all scales.  
As expected, we found that the PANSS amotivation factor was highly correlated with the SANS amotivation 
factor (Table S2). Importantly, this correlation was significantly stronger than the correlation between the 
PANSS amotivation factor and the SANS diminished expression score (z=2.5, p=0.014). Furthermore, the 
PANSS diminished expression factor was highly correlated with the SANS diminished expression factor and 
this correlation was significantly stronger than the correlation between the PANSS diminished expression 
factor and the SANS amotivation factor (z=4.9, p<0.0001). 
The correlation matrix between the BNSS, PANSS and SANS confirmed the strong correlations for the 
factors amotivation and diminished expression between BNSS and PANSS shown in the main text of the 
manuscript (Table S2).  
 
Study 2 – Behavioural validation 
Similarly to BNSS and PANSS, the negative correlation of AUC was significant for SANS amotivation (r=-
0.58, p<0.001) but not for SANS diminished expression (r=-0.17, p=0.37). There was no difference between 
the correlations of AUC with BNSS amotivation and SANS amotivation (z=-1.34, p=0.18), as well as between 
the correlation of AUC with PANSS amotivation and SANS amotivation (z=0.98, p=0.33) (Table S3). 
 
Study 3 – Neural validation 
The SANS factors show a similar pattern of results as the BNSS and the PANSS factors (Table S4). 
Specifically, the strength of the association of ventral striatum signal change with SANS amotivation did 
not differ significantly from that with BNSS amotivation (z=0.07, p=0.9).  
 
The three analyses show better correspondence between BNSS and SANS than between BNSS and PANSS. 
The preference of SANS over PANSS for the assessment of negative symptoms has previously been 
acknowledged, in that the SANS better reflects the defined domains of negative symptoms and uses 
several items to assess each domain (Kirkpatrick et al., 2006). However, our results show that all the three 
scales allow the distinction between the factors amotivation and diminished expression and that either 




Table S1. Factor solutions from the literature used to calculate Amotivation and Diminished expression 
factors for the SANS 
Amotivation Diminished expression 
SANS (Strauss et al., 2013) 





Table S2. Correlation Matrix for BNSS, PANSS and SANS (75 participants) 
























 —  0.542  0.773  0.529  0.815  0.544  





    —  0.650  0.876  0.545  0.927  






       —  0.672  0.811  0.649  





          —  0.548  0.915  






             —  0.577  





                —  
   p-value                 —  
 
 
Table S3. Correlation Matrix for SANS and area under the curve (AUC) reflecting willingness to exert effort 
(N=31)  
    AUC 
AUC  Pearson's r  —   
   p-value  —   
SANS Expression  Pearson's r  -0.169   
   p-value  0.365   
SANS Amotivation  Pearson's r  -0.577   
   p-value  < .001   
  
Table S4. Correlation Matrix for SANS and left ventral striatum activation (N=41) 
    left VS 
left VS  
Pearson's 
r 
 —   
   p-value  —   
SANS Amotivation  
Pearson's 
r 
 -0.533   
   p-value  < .001   
SANS Expression  
Pearson's 
r 
 -0.111   
   p-value  0.495   
  
  
Clinical validation of the PANSS 
In an additional analysis, we included only the 75 patients which exclusively participated in Study 1 and 
not in Study 2 or 3 in order assure full independence. The results for this subgroup were almost identical 
to the full sample (see supplementary material, and supplementary table S1).   
First, the PANSS amotivation factor was highly correlated with the BNSS amotivation factor. Similarly to 
the main result in the full 120 sample, this correlation was significantly stronger than the correlation 
between the PANSS amotivation factor and the BNSS diminished expression score (z=2.8, p<0.005). The 
same was true for the diminished expression factor: the PANSS diminished expression factor was highly 
correlated with the BNSS diminished expression factor and this correlation was significantly stronger than 
the correlation between the PANSS diminished expression factor and the BNSS amotivation factor (z=4.02, 
p=0.0001). 
Table S5. Correlation Matrix for BNSS & PANSS factors (75 participants) 
          
    PANSS Amotivation PANSS Expression BNSS Amotivation 
PANSS Amotivation  Pearson's r  —        
   p-value  —        
PANSS Expression  Pearson's r  0.732  —     
   p-value  < .001  —     
BNSS Amotivation  Pearson's r  0.863  0.696  —  
   p-value  < .001  < .001  —  
BNSS Expression  Pearson's r  0.722  0.915  0.711  
   p-value  < .001  < .001  < .001  
 
 
